Multivalent combined vaccine

Abstract

The invention discloses a multivalent combined vaccine. Each dosage of the multivalent combined vaccine comprises: 15-20 mu g of group-A epidemic neisseria meningitides capsular polysaccharide, 15-20 mu g of group-C epidemic neisseria meningitides capsular polysaccharide, 15-20 mu g of group-Y epidemic neisseria meningitides capsular polysaccharide, 15-20 mu g of group-W135 epidemic neisseria meningitides capsular polysaccharide, 10-20 mu g of group-B meningococcal attenuated live vaccine and 10-20 mu g of measles attenuated live vaccine. The multivalent combined vaccine helps to reduce immunization injection times, reduce immunization cost and increase acceptability of the vaccine; the multivalent combined vaccine helps to provide research direction for satisfying infant demands, and is expected to alleviate infant pain and parent spirit burden; and by utilizing the synergic effects of different vaccines, the multivalent combined vaccine helps to reduce the occurrence probability of bacteremia, enhance the immunogenicity of group-B meningococcal LOS vaccines, or enhance the immunization effect and prolong the immunization time of group-B meningococcal outer membrane protein.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a multivalent combination vaccine. Background technique [0002] Neisseria meningitidis, also known as Neisseria meningitidis or Neisseria meningitidis, or meningococcus for short, is a Gram-negative bacterium best known for causing meningitis. [0003] Neisseria meningitidis is mainly responsible for the occurrence of human meningococcal meningitis, and can also cause other respiratory diseases such as pneumonia. Germs exist in the nasopharyngeal secretions of patients or carriers, and are transmitted through the respiratory tract. The epidemic of meningococcal meningitis has obvious seasonality and periodicity. The incidence rate is high in winter and spring. It usually starts in January every year and peaks in March and April. According to statistics, from February to April every year, the incidence rate of "Emergency Meningitis" accounts for about 60% of the whole year. ,...

AI Technical Summary

Problems solved by technology

Disadvantages of OMV: ① Candidate antigens are highly variable; ② It takes a relatively long process from the isolation of epidemic strains to the application of vaccines; ③ Infants and young children are the main infected population of group N meningitis, and this vaccine is effective in infants and young children. low protective; ④ only short-term immune protection

Defects of LOS vaccines as group B meningococcal vaccines: ① According to the current epidemiological data, the group B meningococcal vaccine with LOS as the main antigen is not enough to protect the whole world; ② The nature of LOS itself determines In order to avoid its weak immunogenicity, if we want to develop this kind of vaccine, we must first improve its immunogenicity; ③The subjects of clinical trials of LOS vaccine are mainly older people, and their immunogenicity is poor in infants and young children

Images